Russian Covid-19 vaccine Sputnik V 95 percent effective, says Russia

Sputnik V coronavirus vaccine: Vladimir Putin ordered the authorities to begin the mass voluntary vaccinations against COVID-19 next week.

Russian coronavirus vaccine: Russia on Tuesday announced that the results of the second interim analysis of clinical trial data of Russian Covid-19 vaccine Sputnik V showed over 95 percent efficacy 42 days after the first dose.

Kirill Dmitriev, Russia’s RDIF sovereign wealth fund head said that recent clinical trial data had shown that Russian COVID-19 vaccine Sputnik V was 91.4 percent effective on day 28 and over 95 percent effective on day 42.

Russian coronavirus vaccine: Russia announced that Russian Covid-19 vaccine Sputnik V over 95 percent efficacy 42 days after the first dose.

Also Read | Third COVID-19 vaccine is ‘almost ready’: Russia

The data was based on 39 confirmed cases and 18,794 patients who got both shots.

The Russian coronavirus vaccine is touted as the world’s first clinically approved vaccine against the novel virus. It is manufactured by the Gamaleya Research Institute in collaboration with the Russian Health Ministry.

Russian coronavirus vaccine: Russia announced that Russian Covid-19 vaccine Sputnik V over 95 percent efficacy 42 days after the first dose.

Also Read | Russia approves second Covid-19 vaccine, says Vladimir Putin

As per the Gamaleya Center experts, it has been confirmed that there was high efficacy of the Sputnik V after double-blind, randomised, placebo-controlled Phase 3 clinical trials.

Russian coronavirus vaccine: Russia announced that Russian Covid-19 vaccine Sputnik V over 95 percent efficacy 42 days after the first dose.

Mikhail Murashko, the Russian health minister said that the data demonstrating the high efficacy of the Sputnik V has given hope that they will soon obtain the most important tool in the fight against the novel coronavirus.

Bathinda triple murder case: In a shocking incident, three family members were reportedly killed at Kamla Nehru Colony in Bathinda.

The interim efficacy was calculated at 3 representative checkpoints – upon reaching 20, 39 and 78 COVID cases among volunteers, both in the placebo group and in the group that received the vaccine.

-PTC News